MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
1.130
-0.020
-1.74%
After Hours: 1.140 +0.01 +0.89% 17:39 07/18 EDT
OPEN
1.180
PREV CLOSE
1.150
HIGH
1.190
LOW
1.130
VOLUME
976.87K
TURNOVER
--
52 WEEK HIGH
5.92
52 WEEK LOW
0.6611
MARKET CAP
129.54M
P/E (TTM)
-0.7572
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FATE last week (0707-0711)?
Weekly Report · 5d ago
Weekly Report: what happened at FATE last week (0630-0704)?
Weekly Report · 07/07 11:11
FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/03 17:05
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 07/03 12:05
Cautious Outlook on Fate Therapeutics Amid Promising Data and Safety Concerns
TipRanks · 07/02 10:15
Weekly Report: what happened at FATE last week (0623-0627)?
Weekly Report · 06/30 11:18
Weekly Report: what happened at FATE last week (0616-0620)?
Weekly Report · 06/23 11:10
Weekly Report: what happened at FATE last week (0609-0613)?
Weekly Report · 06/16 11:17
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Webull offers Fate Therapeutics Inc stock information, including NASDAQ: FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.